Paxlovid for Treatment of Long Covid

Trial ID or NCT#

NCT05576662

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid."

Official Title

Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Linda N. Geng, MD, PhD
Linda N. Geng, MD, PhD
Internal medicine doctor
Clinical Associate Professor, Medicine - Primary Care and Population Health
Upinder Singh

Contact us to find out if this trial is right for you.

Contact

Study Team
650-308-6788

View on ClinicalTrials.gov